196 related articles for article (PubMed ID: 35046520)
1. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
Shohdy KS; Villamar DM; Cao Y; Trieu J; Price KS; Nagy R; Tagawa ST; Molina AM; Sternberg CN; Nanus DM; Mosquera JM; Elemento O; Sonpavde GP; Grivas P; Vogelzang NJ; Faltas BM
Br J Cancer; 2022 Feb; 126(3):430-439. PubMed ID: 35046520
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of Chinese patients with urothelial carcinoma.
Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
[TBL] [Abstract][Full Text] [Related]
3. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
4. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
Vandekerkhove G; Lavoie JM; Annala M; Murtha AJ; Sundahl N; Walz S; Sano T; Taavitsainen S; Ritch E; Fazli L; Hurtado-Coll A; Wang G; Nykter M; Black PC; Todenhöfer T; Ost P; Gibb EA; Chi KN; Eigl BJ; Wyatt AW
Nat Commun; 2021 Jan; 12(1):184. PubMed ID: 33420073
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
[No Abstract] [Full Text] [Related]
6. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
7. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
9. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
[TBL] [Abstract][Full Text] [Related]
10. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.
Parikh AR; Mojtahed A; Schneider JL; Kanter K; Van Seventer EE; Fetter IJ; Thabet A; Fish MG; Teshome B; Fosbenner K; Nadres B; Shahzade HA; Allen JN; Blaszkowsky LS; Ryan DP; Giantonio B; Goyal L; Nipp RD; Roeland E; Weekes CD; Wo JY; Zhu AX; Dias-Santagata D; Iafrate AJ; Lennerz JK; Hong TS; Siravegna G; Horick N; Clark JW; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(8):1877-1885. PubMed ID: 31941831
[TBL] [Abstract][Full Text] [Related]
11. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
12. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
Raja R; Kuziora M; Brohawn PZ; Higgs BW; Gupta A; Dennis PA; Ranade K
Clin Cancer Res; 2018 Dec; 24(24):6212-6222. PubMed ID: 30093454
[TBL] [Abstract][Full Text] [Related]
13. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
15. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
17. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
Coombes RC; Page K; Salari R; Hastings RK; Armstrong A; Ahmed S; Ali S; Cleator S; Kenny L; Stebbing J; Rutherford M; Sethi H; Boydell A; Swenerton R; Fernandez-Garcia D; Gleason KLT; Goddard K; Guttery DS; Assaf ZJ; Wu HT; Natarajan P; Moore DA; Primrose L; Dashner S; Tin AS; Balcioglu M; Srinivasan R; Shchegrova SV; Olson A; Hafez D; Billings P; Aleshin A; Rehman F; Toghill BJ; Hills A; Louie MC; Lin CJ; Zimmermann BG; Shaw JA
Clin Cancer Res; 2019 Jul; 25(14):4255-4263. PubMed ID: 30992300
[TBL] [Abstract][Full Text] [Related]
18. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
19. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
20. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W
Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]